19 results about "Insulin sensitivity" patented technology

This invention relates to the application of oridonin in the preparation of agents that improve muscle function, specifically by improving skeletal muscle dysfunction, enhancing insulin sensitivity, promoting myoblast differentiation into myotube cells, and / or increasing myoblast insulin sensitivity. Using an in vitro C2C12 myoblast model, this invention demonstrates that oridonin can promote myoblast differentiation and growth and increase C2C12 myoblast insulin sensitivity. Through an obesity-induced skeletal muscle dysfunction model, it is demonstrated that oridonin can improve skeletal muscle dysfunction and insulin resistance by increasing muscle strength, muscle endurance, muscle mass, and reducing muscle lipid accumulation. This invention provides new insights for drug research on improving skeletal muscle dysfunction and enhancing insulin sensitivity, and also enriches the pharmacological system of oridonin.

The present invention provides a method for treating obesity or an obesity-related disease or disorder, comprising administering a PYY analog in combination with an incretin, wherein the patient's insulin sensitivity is improved with treatment.

This invention belongs to the field of biomedical technology and discloses the application of NP in the preparation of a glycemic regulator for aging type 2 diabetes. The NP is a nanoscale complex formed by hydrogen bonding of turtle egg peptide with a molecular weight less than 3 kDa and naringenin at a mass ratio of 100:1. The formulation promotes liver glycogen synthesis and repairs pancreatic tissue structure and pancreatic β-cell function by activating the hepatic IRS1 / PI3K / AKT / GSK-3β signaling pathway and upregulating GLUT2 protein expression. The NP provided by this invention can significantly reduce fasting blood glucose levels in aging type 2 diabetic mice, improve oral glucose tolerance, and reduce the area under the blood glucose curve. Simultaneously, by restoring insulin signal transduction, it significantly reduces the insulin resistance index and improves the insulin sensitivity index, with an improvement level approaching that of the classic hypoglycemic drug metformin.

This invention relates to peptide complexes with anti-diabetic activity and their uses. The peptide complexes of this invention promote cellular glucose uptake, inhibit insulin resistance signaling, promote insulin sensitivity signaling, and inhibit apoptosis of pancreatic β-cells, which are insulin-producing cells, thereby exhibiting a blood glucose-lowering effect. Furthermore, this invention also relates to peptides with anti-diabetic and anti-obesity activities and their uses. The peptides of this invention have activities that inhibit insulin resistance signaling, promote insulin sensitivity signaling, and promote lipolysis in adipocytes.

The present application discloses the use of FGF21 / GLP-1 fusion proteins in the preparation of a medicament for preventing and / or treating at least one of type 2 diabetes, obesity, steatohepatitis, and triglyceridemia. The FGF21 / GLP-1 fusion proteins of the present application are effective in treating at least one of type 2 diabetes, obesity, steatohepatitis, and triglyceridemia, and in particular, can reduce at least one of HbA1c, blood glucose, body weight, liver fat content, ALT, AST, glutamyl transpeptidase, triglyceride, total cholesterol, low-density lipoprotein cholesterol, or increase at least one of adiponectin, insulin sensitivity, and beta-cell function in the subject.

This invention discloses the application of verbascoside in the preparation of drugs for treating obesity and related metabolic disorders, relating to the field of biopharmaceuticals. The drug upregulates the expression of phosphorylated AMP-activated protein kinase α and carnitine palmitoyltransferase-1α, while downregulating the expression of sterol regulatory element-binding protein-1c, fatty acid synthase, and acetyl-CoA carboxylase. This application is the first systematic study of the comprehensive intervention effect of verbascoside on diet-induced obesity and related metabolic disorders. In an in vivo obese mouse model, it was demonstrated that verbascoside can significantly inhibit excessive weight gain induced by a high-fat diet, reduce fasting blood glucose and fasting insulin levels, improve dyslipidemia indicators including triglycerides, total cholesterol, non-esterified fatty acids, and low-density lipoprotein cholesterol, enhance insulin sensitivity, and alleviate macrovesicular steatosis and hepatocellular damage.

The application discloses a kind of potential metabolic state modeling gestational diabetes risk assessment and intervention decision method, it is related to medical information technology field, including: first, obtain the minimum metabolic modeling data structure containing individual static information, follow-up observation and intervention data;Second, initialize the latent metabolic state vector formed by insulin sensitivity, beta cell compensatory capacity, fat burden and other latent variables;Then, an observation mapping and state updating mechanism is established, and the state vector is dynamically corrected and updated using follow-up observation and intervention data;Subsequently, based on the updated vector, a metabolic system stability index is calculated to assess patient risk stratification;Finally, by counterfactual reasoning, the state evolution under different hypothetical intervention scenarios is simulated, and the intervention priority and recommendations are output.The present application realizes early identification and precise intervention of risk through microscopic modeling and deduction of latent metabolic state, significantly improving the effectiveness of perinatal and postpartum health management.

This invention belongs to the technical field of functional foods for blood glucose management, specifically relating to a postprandial blood glucose-suppressing composition containing inactivated Akkermansia myxophilus. Existing blood glucose control products have limited effectiveness or significant side effects. The composition of this invention contains inactivated Akkermansia myxophilus and blood glucose-lowering active ingredients such as mulberry leaf extract and chromium yeast. This invention achieves the effects of reducing postprandial blood glucose peaks and improving glucose metabolism through a dual mechanism of slowing carbohydrate absorption and improving insulin sensitivity. The composition of this invention is stable at room temperature and can be formulated into tablets or capsules.

This invention relates to the field of biotechnology, and more particularly to a method for alleviating high-starch-induced liver damage and glucose metabolism disorders in sea bass. The feed formulation proposed in this invention comprises 20%-22% cassava starch and 2%-6% mulberry leaf polysaccharides, among other components. This application discloses that mulberry leaf polysaccharides and the high starch content in the feed form a highly efficient synergistic effect, significantly improving the growth performance of sea bass, effectively reducing the accumulation of glycogen and fat in the liver, and significantly improving liver health. Simultaneously, it optimizes the blood glucose regulation capacity of sea bass, alleviates insulin resistance caused by a high-starch diet, and enhances insulin sensitivity. Furthermore, by activating mechanisms such as the PI3K / Akt signaling pathway, it optimizes the glucose metabolism pathway and promotes efficient energy utilization. The feed formulation of this invention is economical and efficient, providing solid scientific support for the healthy aquaculture of sea bass and powerfully promoting the sustainable development of aquaculture.

The present application relates to a composition for maintaining healthy blood sugar level and its preparation method and application, and belongs to the technical field of health products. The composition for maintaining healthy blood sugar level comprises mulberry leaf extract, cactus extract, prunus domestica extract, glyceryl tributyrate and capsaicin. The present application has the beneficial effect of providing a composition of active ingredients which can effectively reduce the level of cortisol, significantly reduce the blood sugar level, and protect the activity of pancreatic beta cells. The composition is good for restoring insulin sensitivity and controlling weight. The present combination formula is reasonable, the product performance is stable, the preparation is simple, and the industrialized production is easy to realize.

The application belongs to the technical field of medicine preparation, and particularly relates to application of cellulose nanofiber in preparation of medicine for preventing or treating gestational diabetes mellitus. In the application, the CNF has significant adsorption capacity for micro / nano plastic due to its high specific surface area and unique surface characteristics. Moreover, the CNF intervention can effectively reduce the deposition of microplastics in organs such as liver and placenta, and reduce the trans-barrier transport and biological toxicity of harmful particles from the source. In addition, the CNF can effectively repair the intestinal barrier damage caused by microplastic exposure or high-fat diet, and reduce the systemic inflammation level. Furthermore, the CNF intervention can significantly reduce the fasting blood glucose of the microplastic exposure model mouse during pregnancy, improve the area under the curve (AUC) of insulin tolerance test (ITT) and oral glucose tolerance test (OGTT), and restore the insulin sensitivity.

The application discloses a uORF element for regulating chicken insulin receptor expression and application thereof, belongs to the field of molecular biology and genetic engineering, and the nucleotide sequence of the uORF element is shown in any one of SEQ ID NO. 1-2; the application comprises any one of the following: (1) regulating the expression of firefly luciferase in eukaryotic cells; the eukaryotic cells are chicken embryo fibroblasts and chicken preadipocytes; (2) being applied to genetic breeding of chickens, and the genetic breeding is breeding of meat chickens with reduced insulin resistance; (3) application in preparation of a reagent for regulating the expression of chicken insulin receptors. The application can regulate the expression level of INSR, improve insulin sensitivity, and provide material support for research on the mechanism of insulin in regulating blood glucose.

The present invention relates to a peptide complex having an antidiabetic activity and to a use thereof. The peptide complex of the present invention promotes uptake of glucose into cells, suppresses insulin resistance signals, promotes insulin sensitivity signals, and suppresses the death of pancreatic beta cells, which are insulin-producing cells, thereby exhibiting an effect of lowering blood glucose levels. In addition, the present invention relates to a peptide having an antidiabetic activity and an antiobesity activity and to a use thereof. The peptide of the present invention has an activity of suppressing insulin resistance signals, promoting insulin sensitive signals, and promoting fat decomposition in adipocytes.

This invention discloses a KDM4C inhibitor and its applications, relating to the field of biomedical technology. Specifically, this invention discloses the application of the KDM4C inhibitor in any of A1) to A5): A1) preparing a drug for the prevention or treatment of obesity; A2) preparing a drug for reducing weight; A3) preparing a drug for reducing food intake; A4) preparing a drug for reducing insulin sensitivity; A5) preparing a drug for enhancing glucose homeostasis. This is achieved through knockout... Kdm4c Inhibiting KDM4C gene activity or inhibiting KDM4C activity can significantly reduce obesity induced by a high-fat diet, thereby regulating the secretion of related hormones / adipokines, affecting food intake, improving insulin resistance, and enhancing insulin sensitivity, making it a potential target for the treatment of obesity.

The application provides a chickpea perilla composite nutrient powder rich in trace elements and a preparation method thereof, and belongs to the technical field of functional food and nutrient fortifier; the application uses chickpea and perilla powder as carriers, and uses organic trace element chelate with high bioavailability to prepare the chickpea perilla composite nutrient powder rich in trace elements magnesium, copper, selenium, manganese and zinc; the chickpea perilla composite nutrient powder is rich in plant protein and dietary fiber, has low glycemic index (GI) and contains natural vanadium elements, and is helpful for improving insulin sensitivity; perilla seed powder is rich in alpha-linolenic acid (Omega-3), and is helpful for regulating blood lipids and improving cardiovascular circulation; the chickpea perilla composite nutrient powder can precisely supplement nutrients and has high bioavailability, has the advantages of low fat, portability, wide applicability and good practicability.

The application discloses application of Bacteroides dorei in preparation of a medicine for improving maternal and offspring outcomes of gestational diabetes mellitus (GDM). The Bacteroides dorei can significantly reduce random blood glucose of a GDM patient, improve glucose tolerance and insulin sensitivity of the GDM patient, relieve intestinal pathological damage caused by the GDM, improve liver steatosis and systemic fat accumulation caused by the GDM, and restore islet structure damage caused by the GDM. The Bacteroides dorei can significantly improve birth outcomes of offspring of the GDM patient, correct abnormal growth and development trajectories of the offspring, improve sugar metabolism levels of the offspring, and improve neurological development behaviors of the offspring of the GDM.

The present application relates to a kind of traditional Chinese medicine compositions, including the following weight parts of preparation raw materials: Huanglian 15~20 parts, Fashi 15~18 parts, Gualoupi 30~45 parts, Juhong 10~15 parts, Danshen 15~20 parts, Baishu 15~20 parts.The traditional Chinese medicine composition prepared in the present application has obvious effect of resisting non-alcoholic fatty liver disease (NAFLD), compared with Rosuvastatin, can further improve the lipid accumulation and balloon-like change of liver, improve the level of triglyceride (TG), cholesterol (TC), low-density lipoprotein (LDL-C) and high-density lipoprotein (HDL-C) in blood fat, reduce liver damage index glutamic-pyruvic transaminase (ALT), inhibit the expression of inflammatory factors (TNF-alpha and IL-1beta).At the same time, the body weight of NAFLD mouse can be significantly reduced, glucose tolerance can be improved, insulin sensitivity can be improved, insulin resistance can be reduced, and the efficacy of regulating intestinal flora and increasing the abundance of intestinal Akkermansia bacteria can be achieved.

This invention discloses a nutritious functional fruit juice beverage for improving postprandial blood glucose levels and its preparation method, belonging to the technical field of functional foods or health foods. This nutritious functional fruit juice beverage is a compound sea buckthorn juice beverage formed by using sea buckthorn juice, sea buckthorn leaf extract, and mulberry leaf extract as the main raw materials, supplemented with loquat concentrate, inulin, monk fruit extract, and other functional components. This invention verified the product's function of improving postprandial blood glucose levels by constructing a hyperglycemic rat model. This nutritious functional fruit juice beverage achieves its function through a full-link blood glucose control mechanism that inhibits carbohydrate absorption, enhances insulin sensitivity, and reduces hepatic glucose output, as well as by improving the body's antioxidant capacity. This invention provides a theoretical basis and technical support for the development and application of foods that improve postprandial blood glucose levels.